Profile data is unavailable for this security.
About the company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
- Revenue in USD (TTM)2.23bn
- Net income in USD-248.39m
- Incorporated2013
- Employees1.37k
- LocationSarepta Therapeutics Inc215 First Street, Suite 415CAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 274-4000
- Fax+1 (302) 636-5454
- Websitehttps://www.sarepta.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals Inc | 674.07m | -22.74m | 1.41bn | 897.00 | -- | 3.38 | 26.51 | 2.09 | -1.19 | -1.19 | 34.46 | 20.46 | 0.6109 | 2.18 | 3.43 | 751,469.30 | -1.91 | -2.99 | -2.25 | -3.49 | 59.34 | 58.84 | -3.12 | -6.12 | 1.98 | 0.6182 | 0.5841 | -- | 26.20 | 24.36 | -230.19 | -- | 19.60 | -- |
| Ocular Therapeutix Inc | 59.65m | -192.71m | 1.51bn | 274.00 | -- | 5.67 | -- | 25.27 | -1.15 | -1.15 | 0.3559 | 1.67 | 0.1263 | 1.90 | 2.30 | 217,686.10 | -40.79 | -44.65 | -43.67 | -51.24 | 90.67 | 90.65 | -323.09 | -216.33 | 10.14 | -- | 0.2065 | -- | 9.03 | 72.05 | -139.68 | -- | -10.46 | -- |
| BGM Group Ltd | 25.10m | -1.44m | 1.59bn | 323.00 | -- | 1.65 | -- | 63.18 | -0.1964 | -0.1964 | 3.47 | 5.91 | 0.4814 | 4.18 | 14.26 | 77,702.63 | -2.91 | -0.0792 | -3.53 | -0.1065 | 16.39 | 10.38 | -6.04 | -0.0921 | 2.82 | -0.3389 | 0.00 | 2,560.18 | -45.99 | -11.45 | 81.46 | -- | 16.40 | -- |
| Endo Inc | 1.73bn | 5.48bn | 1.63bn | 3.12k | 0.2968 | 1.45 | 0.2813 | 0.941 | 72.02 | 74.43 | 22.76 | 14.78 | 0.3793 | 4.25 | 4.54 | 556,311.30 | 120.01 | -- | 134.54 | -- | 11.14 | -- | 316.41 | -- | 2.02 | 1.15 | 0.6841 | -- | -12.50 | -- | 323.04 | -- | -- | -- |
| Arcutis Biotherapeutics Inc | 212.82m | -129.72m | 1.64bn | 342.00 | -- | 11.49 | -- | 7.71 | -1.04 | -1.04 | 1.71 | 1.20 | 0.5174 | 1.65 | 3.47 | 622,277.80 | -31.54 | -61.20 | -37.92 | -68.48 | 88.39 | -- | -60.95 | -406.29 | 3.37 | -5.35 | 0.43 | -- | 229.74 | -- | 46.58 | -- | 77.12 | -- |
| Immunocore Holdings PLC - ADR | 333.58m | -21.63m | 1.65bn | 493.00 | -- | 8.69 | -- | 4.93 | -0.4451 | -0.4451 | 6.51 | 3.77 | 0.33 | 0.6045 | 5.52 | 676,634.90 | -2.14 | -17.90 | -2.52 | -23.26 | 99.01 | -- | -6.48 | -53.74 | 6.31 | -- | 0.5085 | -- | 24.37 | 56.77 | 7.60 | -- | -1.06 | -- |
| Tarsus Pharmaceuticals Inc | 233.67m | -104.94m | 1.70bn | 323.00 | -- | 4.96 | -- | 7.27 | -2.73 | -2.73 | 6.07 | 8.15 | 0.5498 | 4.86 | 5.06 | 723,448.90 | -24.69 | -33.35 | -29.10 | -37.21 | 92.99 | -- | -44.91 | -125.04 | 5.54 | -- | 0.1737 | -- | 948.62 | -- | 14.97 | -- | 106.47 | -- |
| Sarepta Therapeutics Inc | 2.23bn | -248.39m | 1.79bn | 1.37k | -- | 1.56 | -- | 0.8007 | -2.87 | -2.87 | 20.79 | 11.63 | 0.6677 | 0.6177 | 4.30 | 1,627,821.00 | -7.43 | -12.82 | -9.07 | -15.47 | 81.82 | 85.53 | -11.12 | -37.16 | 2.46 | -1.60 | 0.499 | -- | 52.97 | 37.94 | 143.89 | -- | 18.57 | -- |
| Supernus Pharmaceuticals Inc | 668.00m | 61.91m | 1.80bn | 674.00 | 29.04 | 1.74 | 12.65 | 2.69 | 1.10 | 1.10 | 11.93 | 18.41 | 0.5039 | 1.10 | 4.55 | 991,093.50 | 4.67 | 4.25 | 6.03 | 5.58 | 89.75 | 87.90 | 9.27 | 10.41 | 2.26 | -- | 0.00 | -- | 8.94 | 11.00 | 5,512.84 | -8.16 | -23.33 | -- |
| Harmony Biosciences Holdings Inc | 744.85m | 152.72m | 1.84bn | 246.00 | 12.24 | 2.56 | 10.44 | 2.48 | 2.62 | 2.62 | 12.82 | 12.55 | 0.783 | 26.36 | 8.02 | -- | 16.05 | 15.64 | 19.42 | 19.13 | 78.34 | 79.78 | 20.50 | 20.61 | 3.63 | -- | 0.196 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 481.17m | -16.95m | 2.00bn | 315.00 | -- | 4.37 | -- | 4.16 | -0.2428 | -0.2428 | 6.61 | 6.28 | 0.86 | 2.76 | 17.17 | 1,527,511.00 | -3.03 | -8.31 | -3.54 | -9.52 | 85.83 | -- | -3.52 | -17.33 | 3.43 | -- | 0.00 | -- | 56.60 | -- | -406.68 | -- | -38.71 | -- |
| Vericel Corp | 238.54m | 2.98m | 2.09bn | 357.00 | 685.74 | 7.05 | 209.18 | 8.75 | -0.0141 | -0.0141 | 4.58 | 5.88 | 0.6107 | 4.27 | 4.64 | 668,182.10 | 0.7624 | -1.03 | 0.8444 | -1.18 | 72.54 | 69.10 | 1.25 | -1.61 | 4.58 | -- | 0.0023 | -- | 20.10 | 15.02 | 425.64 | -- | 89.53 | -- |
| Ligand Pharmaceuticals Inc | 181.49m | -132.62m | 2.19bn | 68.00 | -- | 2.75 | -- | 12.08 | -7.12 | -7.12 | 9.73 | 41.27 | 0.1995 | 0.7255 | 5.42 | 2,668,941.00 | -14.58 | 1.82 | -15.22 | 1.92 | 92.81 | 82.57 | -73.07 | 10.30 | 5.02 | -0.2833 | 0.00003 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| Apellis Pharmaceuticals Inc | 775.84m | -223.68m | 2.24bn | 705.00 | -- | 13.64 | -- | 2.89 | -1.79 | -1.79 | 6.23 | 1.31 | 0.9466 | 1.08 | 3.08 | 1,100,482.00 | -27.29 | -61.31 | -35.92 | -76.53 | 83.00 | 86.49 | -28.83 | -157.26 | 3.62 | -5.43 | 0.7341 | -- | 97.02 | -- | 62.57 | -- | -24.96 | -- |
| Twist Bioscience Corp | 347.68m | -191.15m | 2.26bn | 923.00 | -- | 5.12 | -- | 6.49 | -3.26 | -3.26 | 5.90 | 7.35 | 0.5355 | 7.23 | 8.09 | 376,684.70 | -29.44 | -28.50 | -33.07 | -31.56 | 46.70 | 39.40 | -54.98 | -93.82 | 4.24 | -- | 0.00 | -- | 27.69 | 41.91 | -2.01 | -- | -19.22 | -- |
Data as of Jul 03 2025. Currency figures normalised to Sarepta Therapeutics Inc's reporting currency: US Dollar USD
47.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (International Investors)as of 31 Mar 2025 | 9.06m | 9.49% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 8.90m | 9.32% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 8.87m | 9.29% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 4.07m | 4.26% |
| Janus Henderson Investors US LLCas of 31 Mar 2025 | 3.32m | 3.48% |
| Avoro Capital Advisor LLCas of 31 Mar 2025 | 2.67m | 2.80% |
| Wellington Management Co. LLPas of 31 Mar 2025 | 2.58m | 2.70% |
| Farallon Capital Management LLCas of 31 Mar 2025 | 2.34m | 2.45% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2025 | 2.00m | 2.09% |
| Geode Capital Management LLCas of 31 Mar 2025 | 1.82m | 1.91% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
